Natera

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Natera reports robust Q4 results, eyes growth in genetic testing

Natera's Q4 2022 performance reflects strong growth in tests and revenues, particularly in oncology, setting the stage for future success.
The company's strategic milestones, new board appointment, and focus on clinical business growth highlight its resilience and market leadership.
While facing challenges in cost management and market competition, Natera has opportunities to leverage positive industry trends and policy changes for sustained growth.

Natera posts strong Q1 results, focuses on clinical differentiation

Natera's Q1 earnings call highlighted robust financials, strategic focus on clinical differentiation, and efforts to improve margins through ASP and COGS projects. Despite challenges with ASP and gross margins, the company remains optimistic about its trajectory and growth opportunities in women's health and organ health.

Natera reports stellar Q2 results, eyes growth amid regulatory changes

Natera delivered a strong Q2 performance with robust revenue growth, improved margins, and strategic advancements across oncology, women's health, and organ health segments.
The company showcased strengths in clinical utility, peer-reviewed publications, and litigation victories, while also addressing challenges like pricing pressures and regulatory changes.
Opportunities lie in expanding market reach through ACOG meetings, commercial coverage enhancements, and leveraging competitor exits for growth in carrier testing business.
Overall, Natera's revised guidance, financial outperformance, and focus on innovation position the company for continued success and market leadership in the genomics space.

Natera (NTRA) reports robust Q3 earnings, eyes market expansion

Natera (NTRA) delivered strong financial performance in Q3 2023, with raised revenue guidance and improved cash burn guidance.
The company's focus on achieving cash flow breakeven in 2024 while driving innovation and market engagement highlights a strategic growth trajectory.
While facing challenges such as pending lawsuits and regulatory uncertainties, Natera is well-positioned to capitalize on opportunities like market expansion and product innovation.

Natera reports robust earnings, eyes growth through strategic acquisitions

Natera's strong financial performance, strategic acquisitions, and focus on key developments position the company for continued growth.
While challenges like maintaining ASP trends and managing competition exist, opportunities in revenue growth, clinical studies, and guideline expansions offer potential upside.
Careful execution, volume growth, and momentum will be crucial for Natera's success in 2024, supported by confidence in their guidelines and innovative testing approaches.

Natera excels in Q1, eyes revenue growth and margin improvement

Natera's Q1 performance was outstanding, marked by revenue growth, margin expansion, and progress in key clinical areas.
While challenges like replicating exceptional performance and seasonal dips exist, the company is well-positioned for future growth.
Opportunities lie in improving margins, volume growth, and market penetration, supporting Natera's ambitious revenue targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

AUSTIN, Texas, July 19, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera" or the "Company"), a pioneer and global leader in cell-free DNA testing, today reported preliminary results for the quarter ended June 30, 2021 for volume and revenue growth. The Company's revenue growth rate in the second quarter of 2021 was the largest year on year growth in its history as a publicly traded company.

Natera Reports Preliminary Second Quarter 2021 Results

AUSTIN, Texas, July 2, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the 2021 European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO GI), taking place June 30 - July 3, 2021. Data will be presented in colorectal cancer (CRC) and pancreatic cancer.

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer

Natera, Inc. is a leading global diagnostics company developing cell-free DNA ("cfDNA") tests focusing on women's health, oncology, and organ health.

Natera: Leading cfDNA Diagnostics Company Offers Strong Growth And Fair Trading Value

Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.

This Explosive Biotech Is Taking On a Huge New Market

AUSTIN, Texas and SHENZHEN, China, June 24, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, and  BGI Genomics Co., Ltd. , (300676.SZ), one of the world's leading genomics companies, today announced the launch of the BGI/Natera Signatera Assay which is now available to biopharmaceutical customers and clinicians across China.

Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China

Natera pioneered DNA blood tests for cancer remaining after treatment. Rivals like Guardant, Invitae, and Exact Sciences are hot on its heels.

How Natera Is Defending Its Lead in a $15B Cancer-Testing Market

AUSTIN, Texas, June 18, 2021 /PRNewswire/ --  Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted ADLT status for the Signatera molecular residual disease (MRD) test. Obtaining ADLT status confirms that Signatera meets the highly selective criteria established under the Protecting Access to Medicare Act of 2014 (PAMA).

Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS

AUSTIN, Texas, June 16, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a new study in Nature, validating the ability of its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, Signatera, to predict outcomes with immunotherapy in a randomized clinical trial. The study, which can be found here , is Signatera's 12th peer-reviewed publication and is the first publication that shows the predictive capabilities of a molecular residual disease (MRD) test in a large, randomized, multi-center study.

Nature Journal Publishes Prospective, Randomized Study Validating Signatera® for Prediction of Immunotherapy Benefit

CAMBRIDGE, Mass. and AUSTIN, Texas, June 8, 2021 /PRNewswire/ -- Foundation Medicine, Inc. and Natera, Inc. (NASDAQ: NTRA), today announced the launch of the research use version of FoundationOne®Tracker, Foundation Medicine's personalized circulating tumor DNA (ctDNA) monitoring assay.

Foundation Medicine Launches FoundationOne®Tracker ctDNA Monitoring Assay for Research Use in Partnership with Natera

AUSTIN, Texas, June 4, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific innovations in cfDNA testing at the American Transplant Congress' (ATC) 2021 Virtual Connect, taking place June 4-9, 2021. Three posters showcasing the scientific progress and performance of the Prospera test will be presented along with four sponsored presentations featuring leading transplant physicians.

Natera Announces New Prospera™ Data at the ATC 2021 Virtual Connect Conference

Naturally Splendid Enterprises Ltd (FRA:50N) (CVE:NSP) (OTCPINK:NSPDF) has reported its first-quarter results, revealing a narrowing loss compared to the same period of 2020. The company's net loss was C$743,636 during the three months ended March 31, down year-over-year from more than C$1.3 million.

Naturally Splendid trims loss in 1Q results, turns focus to higher-margin products like NATERA Plant Based Foods

AUSTIN, Texas, May 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal's™ true test performance and the differences between tumor-informed and tumor-naive molecular residual disease (MRD) tests. Natera has filed a claim against Guardant in the U.S. District Court for the Western District of Texas, (Docket No.6:21-cv-00540), alleging that Guardant used false and misleading claims to deceive physicians about the performance capabilities of its MRD test, in violation of the Lanham Act.

Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists

AUSTIN, Texas, May 26, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) assay, Signatera, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 4-8, 2021. Two additional studies were presented at the 2021 American Association for Cancer Research (AACR) annual meeting that took place April 9-14, 2021.

New Signatera™ Data in Multiple Myeloma, Colorectal Cancer and Ovarian Cancer Highlights Clinical Utility of MRD in Real-World Settings

AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced initial results from the CIRCULATE-Japan trial, the largest prospective molecular residual disease (MRD)-guided study to date. Part of CIRCULATE-Japan, the prospective, observational GALAXY study uses Natera's personalized and tumor-informed circulating tumor DNA (ctDNA) test, Signatera™, to monitor MRD status in patients with stage II-IV or relapsed colorectal cancer (CRC) who are amenable to radical surgical resection.

Natera to Present Clinical Data from Largest Prospective MRD-Guided Trial in Colorectal Cancer at the 2021 ASCO Annual Meeting

Natera's (NTRA) CEO Steve Chapman on Q1 2021 Results - Earnings Call Transcript

Shares of Natera (NASDAQ:NTRA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 64.44% over the past year to ($0.74), which beat the estimate of ($1.02).

Natera: Q1 Earnings Insights

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2021 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights Generated total revenues of $152.3 million in the first quarter of 2021 compared to $94.0 million in the first quarter of 2020, an increase of 62%.

Natera Reports First Quarter 2021 Financial Results

AUSTIN, Texas, May 3, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present 4 posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. These presentations will highlight the unique applications of the Signatera molecular residual disease (MRD) test in colorectal cancer and multiple myeloma.

Natera to Present New Colorectal Cancer and Multiple Myeloma Data at the 2021 Annual ASCO Meeting

AUSTIN, Texas, April 29, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2021, after the market close on May 6, 2021. Natera will host a conference call and webcast at 1:30 p.m.

Natera Announces First Quarter 2021 Earnings Conference Call

Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCPINK:NSPDF) (FRA:50N) has announced that the third shipping container of Natera Plant Based Foods has arrived from Australia.  In anticipation of demand from an expanding distribution network and e-commerce presence, the company said additional purchase orders are being placed with its Australian manufacturer.

Naturally Splendid says 3rd shipping container of Natera Plant Based Foods has arrived from Australia

AUSTIN, Texas, April 22, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and a global leader in cell-free DNA testing, receives pathway to future coverage for the Prospera donor-derived, cell-free DNA (dd-cfDNA) test to determine transplant rejection status in multiple organs.  Today, the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Program (MoLDX) published a future effective local coverage determination (LCD) that identifies and establishes this pathway to coverage in a broad range of solid organ transplants.

Prospera™ Transplant Assessment Test: Path Established to Expand Future Coverage to Multiple Organs

The stock price of Natera, a clinical genetic testing company, has seen a large 14% drop in just five trading sessions. The decline is driven in part by the broader sell-off in high growth stocks, and profit booking at higher levels.

Can Natera Stock Rebound After A 14% Fall In A Week?

AUSTIN, Texas, April 7, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has implemented the first wave of Panorama AI innovations following the breakthrough results shared earlier from the SMART study. Panorama AI is a new algorithm for the Panorama NIPT that leverages enhanced probabilistic modeling and artificial intelligence-based technology, builds on the unique SNP-based platform, and utilizes information from over 2 million cfDNA tests performed by Natera.

Natera Implements First Wave of Panorama® AI Improvements With Immediate Impact on Patient Experience and COGS

CareDx

Veracyte

These under-the-radar stocks have had incredible growth over the last 5 years, and are all off over 15% from their highs.

3 Cancer Diagnostic Monster Stocks on Sale

AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in non-invasive genetic testing and analysis of cfDNA, and Tesis Labs, a US multi-region lab services provider with labs in Colorado, Texas and Arizona, announced a strategic partnership in the field of prenatal genetic testing. The collaboration will allow Tesis to broaden its portfolio of genetic testing offerings and participate in the fast growing screening market for over 4 million pregnancies in the United States.

News for Natera Stock (NTRA)